Controlled Human Malaria Infection Transmission Model - Phase A
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is to develop a model to test the efficacy of vaccines and/or drugs designed to block
transmission of malaria to mosquitoes and to identify the targets of transmission-blocking
immunity to malaria.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
KEMRI-Wellcome Trust Collaborative Research Program Kenya Medical Research Institute Sanaria Inc. University Hospital Heidelberg
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Fanasil, pyrimethamine drug combination Lumefantrine Piperaquine Primaquine Pyrimethamine Sulfadoxine